Full Press Release Details
("Midatech" or the "Company")
Further re: Notice of General Meeting
- Correction of Typographical Errors
Further to the announcement made on 8 March 2023
providing notice of a general meeting (the "GM") of the Company to be held on 24 March 2023, and the publication and
despatch of a circular to shareholders containing notice of the resolutions to be considered at the GM (the "Notice")
and form of proxy (the "Form of Proxy"), the Company announces the following corrections to certain typographical errors
identified within the Notice and Form of Proxy:
As such errors are administrative in nature, no
new Notice will be published and the aforementioned amendments to Resolution 4 and Resolution 5 will be effected by a motion to be passed
at the GM. Furthermore, no new Form of Proxy will be posted to shareholders but a copy of the corrected Form of Proxy will be made available
on the Company's website at: www.midatechpharma.com/. Any shareholder who wishes to change any proxy instructions already submitted may
do so by submitting a new proxy appointment using the method set out in the notes to the Notice.
| For more information, please contact : Midatech Pharma PLC | |
| Stephen Stamp, CEO, CFO | |
| Tel: +44 (0)29 2048 0180 | |
| www.midatechpharma.com | |
| Strand Hanson Limited (Nominated Adviser and Broker) | |
| James Dance / Matthew Chandler / Rob Patrick | |
| Tel: +44 (0)20 7409 3494 |
| IFC Advisory Limited (Financial PR and UK Investor Relations) | |
| Tim Metcalfe / Graham Herring | |
| Tel: +44 (0)20 3934 6630 | |
| Email: midatech@investor-focus.co.uk | |
| Edison Group (US Investor Relations) Alyssa Factor Tel: +1 (860) 573 9637 Email: afactor@edisongroup.com |